They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Safety was equally impressive. ENV-294 was well tolerated
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
The company spotlights micronutrient’s role in immunity, skin and bone health through digital and radio outreach on National Vitamin C Day
Hands-on clinical workshop in Bengaluru brings together neurologists, ENT specialists and physicians
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
Subscribe To Our Newsletter & Stay Updated
